Literature DB >> 12623113

In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands.

Zi-Fen Su1, Jiang He, Mary Rusckowski, Donald J Hnatowich.   

Abstract

UNLABELLED: The level of alpha(V)beta(3) integrins on endothelial cells is elevated in angiogenesis. The high binding specificity to alpha(V)beta(3) integrins of peptides containing Arg-Gly-Asp (RGD) residues suggests that the radiolabeled RGD peptides may be useful as tumor specific imaging agents. In this research, cyclised peptides containing Arg-Gly-Asp (RGD) and Arg-Gly-Glu (RGE, as control) residues were conjugated with HYNIC and labeled with (99m)Tc.
OBJECTIVE: The goal was to evaluate the influence of co-ligand, either tricine or ethylenediamine-N,N'-diacetic acid (EDDA) on protein and integrin binding and on cellular uptake in culture.
METHODS: The n-octanol/water partition coefficient, binding to bovine serum albumin (BSA) and human umbilical vein endothelial (HUVE) cells, and cell lysate distributions of the radiolabeled peptides were evaluated.
RESULTS: The co-ligands had a significant effect on the labeling efficiency of the HYNIC conjugates and on certain properties of the (99m)Tc complexes. The labeling efficiency with tricine was 10 fold higher and BSA binding was over 8 fold greater compared to EDDA. Both RGD labels showed higher (6 to 28 fold) binding to HUVE cells than that of the RGE labels, indicating binding specificity. After cell-lysis, only a small percentage of the total RGD label that accumulated in the cells was found bound to cellular proteins (9% of RGD/tricine and 5% of RGD/EDDA), implying that over 90% of the radiolabeled peptides were internalized for both radiolabeled RGDs. The number of the RGD molecules bound to proteins was estimated to be approximately three per cell, suggesting that only a small number of alpha(V)beta(3) integrin proteins are expressed on the cells.
CONCLUSIONS: Apart from the differences in radiolabeling, the only important effect of substituting EDDA for tricine as co-ligand on the HYNIC-peptides was the lower degree of serum protein binding. In spite of the lower serum protein binding potential, in vivo tumor accumulation of the RGD/EDDA may not be improved compared to RGD/tricine since quantitation of the cell binding results suggests that the number of alpha(V)beta(3) integrin proteins per cell might be limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623113     DOI: 10.1016/s0969-8051(02)00390-6

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

Review 1.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?

Authors:  Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

2.  Tc-labeling of Peptidomimetic Antagonist to Selectively Target alpha(v)beta(3) Receptor-Positive Tumor: Comparison of PDA and EDDA as co-Ligands.

Authors:  In Soo Shin; Jin Soo Maeng; Beom-Su Jang; Eric You; Kenneth Cheng; King C P Li; Bradford Wood; Jorge A Carrasquillo; S Narasimhan Danthi; Chang H Paik
Journal:  Curr Radiopharm       Date:  2010-01-01

3.  How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.

Authors:  Robert C King; M Bashir-Uddin Surfraz; Stefano C G Biagini; Philip J Blower; Stephen J Mather
Journal:  Dalton Trans       Date:  2007-09-25       Impact factor: 4.390

Review 4.  Molecular imaging of angiogenesis with SPECT.

Authors:  Ingrid Dijkgraaf; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

5.  Synthesis and preliminary evaluation of a new (99m)tc labeled substance p analogue as a potential tumor imaging agent.

Authors:  Saeed Mozaffari; Mostafa Erfani; Davood Beiki; Fariba Johari Daha; Farzad Kobarfard; Saeed Balalaie; Babak Fallahi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

6.  A 99mTc-Labelled Tetrazine for Bioorthogonal Chemistry. Synthesis and Biodistribution Studies with Small Molecule trans-Cyclooctene Derivatives.

Authors:  Alyssa Vito; Hussain Alarabi; Shannon Czorny; Omid Beiraghi; Jeff Kent; Nancy Janzen; Afaf R Genady; Salma A Al-Karmi; Stephanie Rathmann; Zoya Naperstkow; Megan Blacker; Lisset Llano; Paul J Berti; John F Valliant
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

7.  Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDfK.

Authors:  Andrea J North; John A Karas; Michelle T Ma; Philip J Blower; Uwe Ackermann; Jonathan M White; Paul S Donnelly
Journal:  Inorg Chem       Date:  2017-08-02       Impact factor: 5.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.